๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Peking Union Medical College Hospital276 Beijing Tiantan Hospital214 Cancer Institute and Hospital, Chinese Academy of Medical Sciences197 AstraZeneca183 Peking University People's Hospital158
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Beijing

5484 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Validating a Medical AI Fine-Tuning Platform for Major Diseases
NCT07795645Chronic Gastritis, Gastric Cancer (GC), Coronary Artery Disease, Stroke
Beijing Friendship Hospital
Observational
96,000
Beijing
2024-11-01
Recruiting
Memory Training in Insomnia With Cognitive Impairment
NCT06969066Cognitive Therapy/Methods, Insomnia Chronic, Cognitive Dysfunction
Xuanwu Hospital, Beijing
Not applicable
70
Beijing
2024-11-01
Not yet open
Smart Technology Facilitated Patient-centered Venous Thromboembolism Management
NCT06350344Venous Thromboembolism, Digital Health, Health Education
Navy General Hospital, Beijing
Not applicable
2,353
Beijing
2024-11-01
Not yet open
Extreme Capsule Electrical Stimulation for Drug-resistant Focal Epilepsy
NCT06663124Epilepsy, Drug Resistant
Xuanwu Hospital, Beijing
Not applicable
10
Beijing
2024-11-01
Recruiting
Effects of Relaxation Training and Stimulus Control in Chronic Insomnia Patients
NCT06658171Chronic Insomnia
Xuanwu Hospital, Beijing
Not applicable
88
Beijing
2024-11-01
Not yet open
ED50 of Sufentanil for Intraoperative Analgesia
NCT06662656Laparoscopic Cholecystectomy, Analgesics๏ผŒOpioid
China International Neuroscience Institution
Observational
26
Beijing
2024-11-01
Recruiting
Digital Early Warning System for Acute Lung Injury in Liver Surgery
NCT07070362Acute Lung Injury(ALI), Liver Cirrhosis, ARDS, Human, MASLD
Beijing Tsinghua Chang Gung Hospital
Observational
3,000
Beijing, Chongqing, Qingdao
2024-11-01
Recruiting
Ba Duan Jin for CI With Hyperarousal/Anxiety
NCT06969079Mind-Body Therapies, Insomnia Chronic
Xuanwu Hospital, Beijing
Not applicable
84
Beijing
2024-11-01
Recruiting
Thread Embedding Acupuncture Therapy for Weight Loss
NCT06653530Obesity and Overweight
Beijing Hospital of Traditional Chinese Medicine
Not applicable
400
Beijing
2024-11-01
Recruiting
Impact of Analytic-integrative Cognitive Behavioural Therapy on Acute Insomnia Disorder (Stress)
NCT06967922Acute Insomnia Disorder
Xuanwu Hospital, Beijing
Not applicable
70
Beijing
2024-11-01
Recruiting
Evaluation of the Efficacy of MACitentan in the Treatment of CoronaryMICrovascular Angina (MACMIC)
NCT06811831Coronary Microvascular Angina, Macitentan
DrugMacitentan
China-Japan Friendship Hospital
Phase EARLY_PHASE1
30
Beijing
2024-11-01
Recruiting
Longitudinal Cohort of Thrombosis and Hemostasis Diseases
NCT06727669Immune Thrombocytopenia, Thrombotic Thrombocytopenic Purpura, Hemophilia A, Acquired, Disseminated Intravascular Coagulation
Peking University People's Hospital
Observational
3,000
Beijing, Zhengzhou, Chongqing
2024-11-01
Not yet open
A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway
NCT06614751Solid Cancers, BRCA Mutation, HRD Cancer, Breast Cancer
Danatlas Pharmaceuticals Co., Ltd
Phase 1
112
Beijing, Beijjing
2024-11-01
Recruiting
Effect of MIT for CI With Anxiety
NCT06969053Chronic Insomnia, Anxiety Disorders
Xuanwu Hospital, Beijing
Not applicable
70
Beijing
2024-11-01
Recruiting
Using Multiparametric Flow Cytometry to Detect Peripheral Blood and Bone Marrow Leukaemia Stem Cells for Relapse Prediction in P-AML
NCT06452732Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Peking University People's Hospital
Observational
283
Beijing
2024-11-01
Active, closed
Effect of Vitamin D and Folic Acid on Mild Cognitive Impairment
NCT07486141Mild Cognitive Impairment
Capital Medical University
Not applicable
380
Beijing
2024-11-01
Recruiting
The Effect of Standard Cognitive-behavioral Therapy+Transcranial Alternating Current on Refractory Insomnia Disorder
NCT06969040Insomnia
Xuanwu Hospital, Beijing
Not applicable
70
Beijing
2024-11-01
Recruiting
Research on Clinical Recovery and Maintenance Strategies for CHB
NCT06803368Chronic Hepatitis b, Hepatitis B Vaccine
Beijing Municipal Administration of Hospitals
Not applicable
285
Beijing
2024-11-01
Active, closed
Evaluating the Effectiveness of Intervention Based on the Model of Occupational Harmony in Patients With Sleep Disorders
NCT06558929Circadian Rhythm Sleep-Wake Disorder
Peking University First Hospital
Not applicable
40
Beijing
2024-11-01
Not yet open
Drug Eluting Stenting and Short Dual Antiplatelet Therapy for Preventing Recurrent Stroke in Vertebral Stenosis Registry Study
NCT06683300Vertebral Artery Stenosis
Beijing Tiantan Hospital
Observational
520
Beijing
2024-11
Not yet open
Identification Of High-risk Coronary Plaques By Multimodal Intravascular Imaging
NCT06681155Coronary Arterial Disease (CAD), Acute Coronary Syndromes
Chinese PLA General Hospital
Observational
500
Shenzhen, Wuhan, Changchun, Xi'an, รœrรผmqi, Hangzhou, Beijing
2024-11
Not yet open
A Clinical Trial to Evaluate the Safety and Tolerability of TQB3911 Tablets in Patients With BCR::ABL Fusion Gene Positive Leukemia
NCT06672263Chronic Myelogenous Leukemia
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
120
Beijing, Nanning, Zhengzhou, Shanghai, Hangzhou
2024-11
Not yet open
A Study of the Effect and Safety of HS-10390 in the Treatment of Patients with Primary IgA Nephropathy
NCT06635772Immunoglobulin a Nephropathy
DrugsHS-10390·Irbesartan
Hansoh BioMedical R&D Company
Phase 2
90
Beijing
2024-11
Recruiting
A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNฮฑ in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)
NCT06650852Chronic Hepatitis B Virus (HBV) Infection
DrugsPEG-IFNฮฑ·Elebsiran
Brii Biosciences Limited
Phase 2
250
Beijing, Guangzhou, Shenzhen, Shanghai, Chengdu, Hangzhou
2024-10-31
Recruiting
Prone Position Assessed by 3D EIT
NCT07083973ARDS (Acute Respiratory Distress Syndrome), Respiratory Failure
Peking Union Medical College Hospital
Observational
30
Beijing
2024-10-31
Recruiting
Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML
NCT06741722AML, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Beijing 302 Hospital
Phase 2
20
Beijing
2024-10-31
Recruiting
A First-in-Human Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of a Novel CRISPR RNA-editing Therapy in Patients with Mecp2 Duplication Syndrome, a Rare Orphan Disease (HERO)
NCT06615206MECP2 Duplication Syndrome
HuidaGene Therapeutics Co., Ltd.
Not applicable
6
Beijing
2024-10-30
Active, closed
A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06711900Non-Small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
432
Beijing, Changchun, Changcun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou
2024-10-30
Recruiting
A Study of GNC-077 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
NCT06609187Breast Cancer, Solid Tumor
DrugGNC-077
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
20
Beijing
2024-10-30
Recruiting
Evaluation of Safety, Efficacy, and Pharmacokinetics of BT-114143 Injection in Patients With Abnormal Uterine Bleeding
NCT07169214Abnormal Uterine Bleeding
DrugBT-114143
ScinnoHub Pharmaceutical Co., Ltd.
Phase 1
39
Beijing
2024-10-30
By invitation
Adaptive Cognitive Training on Cognitive Function in Elderly Hypertension Patients in the Community
NCT06512922Hypertension, Condition, Aging
Peking University
Not applicable
120
Beijing
2024-10-29
Recruiting
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
NCT06663332Crohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Arthritis, Juvenile
DrugGuselkumab
Janssen Research & Development, LLC
Phase 3
196
Beijing, Changzhou, Hangzhou, Shanghai, Shenyang
2024-10-29
Recruiting
An Open-label, Multi-center, Dose-escalation and Cohort Expansion Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Efficacy of ACR246 in Patients With Advanced Solid Tumors
NCT06238401Advanced Solid Tumors
Hangzhou Adcoris Biopharmacy Co., Ltd
Phase 1
77
Beijing, Zhejiang, Shandong, Shanghai
2024-10-29
By invitation
Adaptive Cognitive Training on Cognitive Function in Elderly Diabetes Patients in the Community
NCT06524388Cognition, Diabetes Mellitus, Type 2, Aging
Fanfan Zheng
Not applicable
120
Beijing
2024-10-29
Recruiting
A Study of BGM0504 Injection in Participants with Obesity or Overweight
NCT06704581Overweight or Obesity
DrugsBGM0504 Administered·BGM0504
BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd.
Phase 3
620
Beijing
2024-10-28
Recruiting
Rapid dFLC Response Predict CHR in AL Amyloidosis
NCT06627309Systemic AL Amyloidosis
Peking University People's Hospital
Observational
50
Beijing, Harbin, Nanjing, Shenyang, Xi'an
2024-10-26
Active, closed
Study on Music Intervention of Non-clinical College Students
NCT06658431Depression Anxiety Disorder
Ye Zhiyin
Not applicable
60
Beijing
2024-10-24
Active, closed
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
NCT06653153Alzheimer's Disease
Eli Lilly and Company
Phase 3
1,400
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hefei, Jinan, Luoyang
2024-10-24
Recruiting
A Prospective Study Evaluating the Impact of Conservative Management on Retained Products of Conception and EMV
NCT06862089Retained Products of Conception, Miscarriage, Conservative Management
Fu Xing Hospital, Capital Medical University
Observational
120
Beijing
2024-10-23
Recruiting
A Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
NCT06644118Multiple Myeloma
Zhejiang University
Phase 1
58
Beijing, Xiโ€™an, Hangzhou
2024-10-23
Recruiting
Value of Super-resolution Ultrasonography in Differentiating Benign and Malignant Lymph Nodes
NCT07155954Lymphadenopathy, Lymphnode Metastasis, Lymphoma, Lymphatic Tuberculosis
Peking University Third Hospital
Observational
779
Beijing
2024-10-23
Recruiting
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
NCT06629779Metastatic Castration-Resistant Prostate Cancer
DrugsMevrometostat·Enzalutamide
Pfizer
Phase 3
900
Wuhu, Beijing, Fuzhou, Guangzhou, Shantou, Guilin, Xinxiang, Zhengzhou
2024-10-22
Not yet open
Levofloxacin Plus Metronidazole Suppositories Versus Levofloxacin Co-administered with Metronidazole Tablets in Chronic Endometritis
NCT06650540IVF
DrugLevofloxacin
Peking University Third Hospital
Not applicable
800
Beijing
2024-10-22
Recruiting
A Study in Chinese Patients With Acquired Blepharoptosis
NCT06683651Blepharoptosis
Santen Pharmaceutical Co., Ltd.
Phase 3
180
Hefei, Beijing, Shantou, Guiyang, Zhengzhou, Haโ€™erbin, Wuhan, Xiangyang
2024-10-22
Active, closed
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
NCT06551324Metastatic Castrate Resistant Prostate Cancer (mCRPC)
DrugsTaxotere·Mevrometostat·Enzalutamide·Paclitaxel
Pfizer
Phase 3
600
Wuhu, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Guilin, Wuhan
2024-10-21
Recruiting
Opioid-free Anesthesia Protocol for Neurosurgical Supratentorial Tumor Resection
NCT06607029Supratentorial Tumors
Beijing Tiantan Hospital
Not applicable
170
Beijing
2024-10-21
Active, closed
A Clinical Trial With KJ103 in Anti-GBM Disease
NCT06607016Anti-Glomerular Basement Membrane Disease
Shanghai Bao Pharmaceuticals Co., Ltd.
Phase 2
12
Beijing
2024-10-21
Recruiting
TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas
NCT06640582Brain Tumor, Brain Metastases, Brain Cancer, Glioma
DrugsTumor Infiltrating Lymphocytes·Interleukin-2·Fludarabine·Cyclophosphamide
Essen Biotech
Phase 1/2
85
Beijing
2024-10-20
Recruiting
A Study on the Efficacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial Hypertension
NCT06554301Pulmonary Arterial Hypertension
China National Center for Cardiovascular Diseases
Phase 1
72
Beijing
2024-10-20
Not yet open
Clinical Study of Radiotherapy Combined With Camrelizumab and Apatinib in the Treatment of Liver Cancer Patients .
NCT06632522Liver Cancer
Beijing Tsinghua Chang Gung Hospital
Phase 2
46
Beijing
2024-10-20
Not yet open
"Eye" Education for Parents and Myopia Control in Children
NCT06652594Children, Health Education, Anxiety
Beijing Tongren Hospital
Not applicable
498
Beijing
2024-10-19
Recruiting
A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
NCT06544499Primary Immune Thrombocytopenia (ITP)
DrugEfgartigimod
argenx
Phase 3
69
Beijing, Bengbu, Chengde, Hohhot, Huai'an, Huizhou, Tianjin, Wuhan
2024-10-18
Active, closed
A Phase 1 Study to Evaluate the Safety/Tolerability, PK/PD of RG002C0106 Injection in Healthy Adults
NCT06494527Safety Issues
DrugRG002C0106
Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.
Phase 1
30
Beijing
2024-10-18
Recruiting
PRospective Observation on CErebral microvaScular Structure and Function
NCT06579677Cerebral Microvascular Dysfunction, Cerebral Small Vessel Diseases, Cognitive Dysfunction, Cerebrovascular Disorders
Beijing Tiantan Hospital
Observational
3,500
Beijing
2024-10-18
Recruiting
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
NCT06662786Colorectal Neoplasms
DrugsLeucovorin calcium/Levoleucovorin·Irinotecan Hydrochloride·Amivantamab·Oxaliplatin
Janssen Research & Development, LLC
Phase 3
1,000
Beijing, Changchun, Changsha, Guangzhou, Hangzhou, Harbin, Huizhou, Nanchang
2024-10-18
Recruiting
Correlation Analysis of POD and pNCD in Elderly Patients With Gastrointestinal Neoplasms
NCT06466096Postoperative Delirium, Postoperative Neurocognitive Disorder, Gastrointestinal Surgery
Xuanwu Hospital, Beijing
Observational
165
Beijing
2024-10-18
Active, closed
Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 Mutation
NCT06780930Residual or Recurrent Grade 2 IDH Mutant Glioma
DrugVorasidenib
Servier
Phase 3
57
Shenzhen, Chengdu, Beijing, Shanghai, Xi'an
2024-10-18
Recruiting
Efficacy and Safety Study of Endovascular Treatment of Asymptomatic Carotid Artery Stenosis
NCT06899399Asymptomatic Carotid Artery Stenosis
Beijing Tiantan Hospital
Not applicable
982
Beijing
2024-10-18
Recruiting
Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors
NCT06598800Advanced Solid Tumor
BeOne Medicines
Phase 1
153
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Shijiazhuang, Harbin, Wuhan
2024-10-18
Active, closed
A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)
NCT06643481Amyotrophic Lateral Sclerosis (ALS)
DrugVHB937
Novartis Pharmaceuticals
Phase 2
251
Beijing
2024-10-17
Recruiting
A Study of BL-B01D1 in Patients With Recurrent Glioblastoma
NCT06598787Recurrent Glioblastoma
DrugIza-bren
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
20
Beijing
2024-10-17
Recruiting
Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus
NCT06585514Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
Beijing GoBroad Hospital
Phase 1/2
18
Beijing
2024-10-17
Not yet open
An IIT Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Single Intrathecal Injection of SNUG01 in Patients with Amyotrophic Lateral Sclerosis
NCT06645197Amyotrophic Lateral Sclerosis (ALS)
DrugSNUG01
Peking University Third Hospital
Phase EARLY_PHASE1
7
Beijing, Fujian, Nanjing, Chengdu, Hangzhou
2024-10-16
Recruiting
Long-term Impact of Inhaled Tobramycin for Pseudomonas Aeruginosa Eradication in Bronchiectasis (ERASE II)
NCT06760273Bronchiectasis Adult
Shanghai Pulmonary Hospital, Shanghai, China
Observational
364
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shenzhen, Zhanjiang, Nanning
2024-10-16
Recruiting
Safety and Effectiveness Evaluation of Spinal Laminectomy Robot
NCT06593574Lumbar Spinal Stenosis, Lumbar Disc Herniation
Peking University Third Hospital
Not applicable
70
Beijing, Guangzhou, Hangzhou
2024-10-15
Active, closed
MRD in PAAD Adjuvant Therapy
NCT06867146The Role of Molecular Residual Disease in the Treatment Strategy and Prognosis Prediction of Pancreatic Cancer Patients Undergoing Adjuvant Therapy, Molecular Residual Disease, Pancreatic Cancer, Adjuvant Therapy
Peking Union Medical College Hospital
Not applicable
60
Beijing
2024-10-15
Recruiting
Efficacy of Self-expandable and Balloon-expandable Valves in Patients With Ascending Aortic Dilation
NCT06743568Aortic Stenosis, Ascending Aortic Dilatation
China National Center for Cardiovascular Diseases
Not applicable
100
Beijing, Shenzhen, Kunming
2024-10-15
Not yet open
Multicenter Registration Study on Allergic Bronchopulmonary Aspergillosis
NCT06645210Allergic Bronchopulmonary Aspergillosis
Peking University Third Hospital
Observational
300
Beijing
2024-10-15
Recruiting
Acupuncture for ADHD: Acupoint Data Mining, Clinical Effectiveness, and Interviews to Explore Treatment Outcomes.
NCT06860763Acupuncture, ADHD - Attention Deficit Disorder With Hyperactivity, Children, Interview
The Third Affiliated Hospital of Beijing University of Chinese Medicine
Not applicable
120
Beijing
2024-10-15
Not yet open
Neoadjuvant With Tฮฑ1 Plus Immuno-chemotherapy for Resectable NSCLC
NCT06607926Resectable Non-Small-Cell Lung Cancer
DrugsThymalfasin·Tislelizumab
Xuanwu Hospital, Beijing
Not applicable
40
Beijing
2024-10-15
By invitation
LORLATINIB-related HYPERLIPIDEMIA in ALK+ Non-Small Cell Lung Cancer
NCT06876675Non-Small Cell Lung Cancer, Hyperlipidemia
Peking University Third Hospital
Observational
167
Beijing
2024-10-15
Active, closed
Daratumumab Combined With Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis With Translocation (11;14)
NCT06629818Light Chain (AL) Amyloidosis
DrugsDaratumumab·Venetoclax·Dexamethasone
Peking Union Medical College Hospital
Phase 2
36
Beijing
2024-10-15
Not yet open
To Evaluate Efficacy and Safety of TopicalKX-826 Solution in Chinese Male Patients With Androgenetic Alopecia
NCT06622824Androgenetic Alopecia (AGA)
Suzhou Kintor Pharmaceutical Inc,
Phase 2/3
756
Beijing
2024-10-15
Active, closed
Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLC
NCT06827145Non-Small-Cell Lung Cancer
DrugsVebreltinib·Osimertinib
National Cancer Center, China
Phase 2
30
Beijing
2024-10-14
Recruiting
LIVERAGEโ„ข: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
NCT06632444Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis
Boehringer Ingelheim
Phase 3
1,800
Beijing, Changchun, Changsha, Changzhou Shi, Chengdu, Chongqing, Foshan, Fuzhou
2024-10-14
Recruiting
Efficacy of Lactobacillus Paracasei LC19 on Type 2 Diabetes
NCT06639425Type 2 Diabetes
Beijing Chao Yang Hospital
Not applicable
60
Beijing
2024-10-12
Active, closed
A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer
NCT06561607Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
542
Bengbu, Hefei, Beijing, Quanzhou, Zhangzhou, Lanzhou, Wuwei, Guangzhou
2024-10-11
Recruiting
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations
NCT06581432Solid Tumours
DrugZongertinib
Boehringer Ingelheim
Phase 2
588
Beijing, Changsha, Hangzhou, Hefei, Nanchang, Nanjing, Shanghai, Wuhan
2024-10-11
Not yet open
Mechanisms of Mindfulness Intervention: Cognitive Flexibility Dose Manipulation
NCT06622122Emotional Distress
Peking University
Not applicable
300
Beijing
2024-10-11
Recruiting
Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma
NCT06348264Salivary Gland Neoplasm Duct
DrugsLeuprolide acetate·Rezvilutamide
Peking University First Hospital
Phase 2
37
Beijing
2024-10-10
Active, closed
Regular Physical Exercise in Patients With Symptomatic Intracranial Arterial Stenosis
NCT06615726Ischemic Stroke, Transient Ischemic Attack
Capital Medical University
Phase 3
1,300
Fuyang, Huainan, Suzhou, Wuhu, Beijing, Chongqing, Zhangzhou, Foshan
2024-10-10
By invitation
Clinical Study on the Combination of Xiaoyu Zhitong Formula and Lymphatic Drainage Technique to Improve the Symptoms of Knee Pain and Swelling in Cold Dampness Obstruction Type
NCT06911437Knee Osteoarthritis (OA)
tang jie
Observational
100
Beijing
2024-10-10
Recruiting
Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis
NCT06418594HER2-negative Breast Cancer Brain Metastases
Beijing 302 Hospital
Phase 2
30
Beijing
2024-10-10
Recruiting
Hypofractionated Postoperative Regional Nodal Irradiation for Patients With Intermediate-risk Breast Cancer
NCT06757621Breast Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3
3,142
Beijing
2024-10-10
Recruiting
Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of IPM514 in Patients with Esophageal Squamous Cell Carcinoma
NCT06690476Esophageal Squamous Cell Carcinoma
DrugsEscalation·Tislelizumab
Peking University
Phase EARLY_PHASE1
74
Beijing
2024-10-10
Recruiting
ZR-MTX for PIOL Phase II Trial
NCT06973811Primary Intraocular Lymphoma
DrugsMethotrexate·Zanubrutinib·Rituximab
Peking Union Medical College Hospital
Phase 2
47
Beijing
2024-10-10
Recruiting
The Effect of Repetitive Transcranial Magnetic Stimulation for Internet Gaming Disorder
NCT06634498Internet Gaming Disorder
Jin-tao Zhang
Not applicable
35
Zhenjiang, Beijing
2024-10-10
Recruiting
A Study of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus
NCT06535412Systemic Lupus Erythematosus
ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.
Phase 1/2
218
Beijing
2024-10-10
Recruiting
A Bioequivalence Study of PP3M in Patients With Schizophrenia
NCT07493551Schizophrenia
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Not applicable
260
Beijing
2024-10-09
Active, closed
Identify Effective Doses of LY01021 in Controlled Ovarian Hyperstimulation (COH) for Female Subjects Undergoing Assisted Reproductive Technology (ART)
NCT07236476Assisted Reproduction
Luye Pharma Group Ltd.
Phase 2
90
Beijing
2024-10-09
By invitation
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SSS39 Injection in Healthy Chinese Subjects
NCT07057726Safety and Tolerability in Healthy Volunteers
Shenyang Sunshine Pharmaceutical Co., LTD.
Phase 1
48
Beijing
2024-10-09
Recruiting
Efficacy Evaluation Study of BAT5906 and Lucentisยฎ in Patients With Diabetic Macular Edema
NCT07515079Diabetic Macular Edema (DME)
DrugLucentis
Bio-Thera Solutions
Phase 3
406
Beijing, Chongqing, Lanzhou, Guangzhou, Shantou, Shenzhen, Nanning, Zunyi
2024-10-09
Recruiting
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
NCT06470048Diffuse Cutaneous Systemic Sclerosis
DrugIanalumab
Novartis Pharmaceuticals
Phase 2
200
Nanning, Zhengzhou, Changchun, Chengdu, Ningbo, Beijing, Tianjin
2024-10-09
Recruiting
A Phase I Clinical Study of Intratumoral Injection GC001 in Patient With Recurrent or Progressive Gliomas
NCT06660056High-grade Gliomas
GONGCHU Biotechnology Co., Ltd
Phase 1
35
Beijing
2024-10-08
Active, closed
An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE).
NCT06335979Systemic Lupus Erythematosus, SLE
DrugPIT565
Novartis Pharmaceuticals
Phase 1
54
Beijing
2024-10-08
Active, closed
To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis
NCT06552520Atopic Dermatitis
DrugTQH2722
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
500
Bengbu, Tongling, Wuhu, Beijing, Chongqing, Xiamen, Guangzhou, Shenzhen
2024-10-08
Recruiting
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression โ‰ฅ 1%
NCT06561386Non-small Cell Lung Cancer
DrugsRelatlimab·Nivolumab·Pemetrexed·Cisplatin
Bristol-Myers Squibb
Phase 3
1,000
Hefei, Beijing, Chongqing, Wanzhou, Fuzhou, Guangzhou, Huizhou, Liuzhou
2024-10-07
Recruiting
Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma
NCT06644430Advanced Hepatocellular Carcinoma, Lung Cancer, Oligometastasis, Ablation
Sun Yat-sen University
Observational
470
Beijing
2024-10-04
Recruiting
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06417814Metastatic Non-small Cell Lung Cancer
DrugsTagrisso·Dato-DXd·Osimertinib·Pemetrexed
AstraZeneca
Phase 3
744
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Deyang, Ganzhou
2024-10-04
Recruiting
A Study of BG-C477 in Participants With Advanced Solid Tumors
NCT06596473Advanced Solid Tumors
DrugTislelizumab
BeOne Medicines
Phase 1
310
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Jiamusi, Zhengzhou
2024-10-03
Rows per page Showing 3001–3100 of 5484
Previous 29 30 31 32 33 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing?page=31

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 5,484 of those studies with a site in Beijing.

How many clinical trials are recruiting in Beijing?

3,341 of the 5,484 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 966 have not yet opened recruitment, 1,001 are active but closed to new participants, and 176 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.